Bez Maxim, Pelled Gadi, Gazit Dan
Medical Corps, Israel Defense Forces, Israel; Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA; Skeletal Biotech Laboratory, Faculty of Dental Medicine, The Hebrew University of Jerusalem, Ein Kerem, Jerusalem, Israel; Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA; Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Bone. 2020 Aug;137:115449. doi: 10.1016/j.bone.2020.115449. Epub 2020 May 21.
Musculoskeletal disorders are common and can be associated with significant morbidity and reduced quality of life. Current treatments for major bone loss or cartilage defects are insufficient. Bone morphogenetic proteins (BMPs) are key players in the recruitment and regeneration of damaged musculoskeletal tissues, and attempts have been made to introduce the protein to fracture sites with limited success. In the last 20 years we have seen a substantial progress in the development of various BMP gene delivery platforms for several conditions. In this review we cover the progress made using several techniques for BMP gene delivery for bone as well as cartilage regeneration, with focus on recent advances in the field of skeletal tissue engineering. Some methods have shown success in large animal models, and with the global trend of introducing gene therapies into the clinical setting, it seems that the day in which BMP gene therapy will be viable for clinical use is near.
肌肉骨骼疾病很常见，可能会导致严重的发病率和生活质量下降。目前针对严重骨质流失或软骨缺损的治疗方法并不充分。骨形态发生蛋白（BMPs）是受损肌肉骨骼组织募集和再生的关键因素，人们曾尝试将该蛋白引入骨折部位，但成效有限。在过去20年里，我们在针对多种病症的各种BMP基因递送平台的开发方面取得了重大进展。在这篇综述中，我们涵盖了使用多种技术进行BMP基因递送以促进骨和软骨再生所取得的进展，重点关注骨骼组织工程领域的最新进展。一些方法在大型动物模型中已显示出成效，并且随着将基因疗法引入临床的全球趋势，BMP基因疗法有望用于临床的日子似乎已近在咫尺。
